Phase 2 trial of montelukast oral film approved in Sweden
IntelGenx has won approval from the Swedish Medical Products Agency (MPA) to conduct a Phase 2 trial on Montelukast Versafilm, its proprietary oral thin film formulation, in people with Parkinson’s disease. The Phase 2 MONTPARK multicenter study will investigate the effectiveness of oral high-dose Montelukast on the progression…